Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper...

Descripción completa

Detalles Bibliográficos
Autores principales: Uz, B., Bektas, O., Eliacık, E., Goker, H., Erbilgin, Y., Sayitoglu, M., Sayinalp, N., Aksu, S., Buyukasik, Y., Ozcebe, O., Haznedaroglu, I. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420724/
https://www.ncbi.nlm.nih.gov/pubmed/22937303
http://dx.doi.org/10.1155/2011/263725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420724/
https://www.ncbi.nlm.nih.gov/pubmed/22937303
http://dx.doi.org/10.1155/2011/263725

Ejemplares similares